AU2017358367B2 - Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH) - Google Patents

Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH) Download PDF

Info

Publication number
AU2017358367B2
AU2017358367B2 AU2017358367A AU2017358367A AU2017358367B2 AU 2017358367 B2 AU2017358367 B2 AU 2017358367B2 AU 2017358367 A AU2017358367 A AU 2017358367A AU 2017358367 A AU2017358367 A AU 2017358367A AU 2017358367 B2 AU2017358367 B2 AU 2017358367B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
extended
pirfenidone
treatment
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017358367A
Other languages
English (en)
Other versions
AU2017358367A1 (en
Inventor
Juan Socorro ARMENDÁRIZ BORUNDA
Nadiel HERNÁNDEZ ALDANA
José Agustín Rogelio MAGAÑA CASTRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excalibur Pharmaceuticals Inc
Original Assignee
Excalibur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excalibur Pharmaceuticals Inc filed Critical Excalibur Pharmaceuticals Inc
Publication of AU2017358367A1 publication Critical patent/AU2017358367A1/en
Application granted granted Critical
Publication of AU2017358367B2 publication Critical patent/AU2017358367B2/en
Priority to AU2024200737A priority Critical patent/AU2024200737A1/en
Assigned to EXCALIBUR PHARMACEUTICALS, INC. reassignment EXCALIBUR PHARMACEUTICALS, INC. Request for Assignment Assignors: Cell Therapy and Technology S.A. DE C.V.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017358367A 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH) Active AU2017358367B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200737A AU2024200737A1 (en) 2016-11-11 2024-02-07 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2016/014775 2016-11-11
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200737A Division AU2024200737A1 (en) 2016-11-11 2024-02-07 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Publications (2)

Publication Number Publication Date
AU2017358367A1 AU2017358367A1 (en) 2019-05-30
AU2017358367B2 true AU2017358367B2 (en) 2023-11-09

Family

ID=61193005

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017358367A Active AU2017358367B2 (en) 2016-11-11 2017-11-09 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (NAFLD/NASH)
AU2024200737A Pending AU2024200737A1 (en) 2016-11-11 2024-02-07 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200737A Pending AU2024200737A1 (en) 2016-11-11 2024-02-07 Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (2) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3716975A4 (en) * 2017-11-28 2022-01-12 Eiger Biopharmaceuticals, Inc. METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
EP4232063A4 (en) * 2020-10-23 2025-01-01 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF TUMOR NECROSIS FACTOR-ALPHA AND TRANSFORMING GROWTH FACTOR-BETA AND THEIR USES
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
EP2907506A1 (en) * 2011-07-19 2015-08-19 Cell Therapy And Technology, S.A. De C.V. Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
EP2907506A1 (en) * 2011-07-19 2015-08-19 Cell Therapy And Technology, S.A. De C.V. Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEPATOLOGY, vol. Vol.64,No.1,Supplement.1, JPN6021032629, October 2016 (2016-10-01), pages 767 - 768, ISSN: 0004576519 *

Also Published As

Publication number Publication date
AR110057A1 (es) 2019-02-20
CL2019001280A1 (es) 2019-07-19
KR20190084056A (ko) 2019-07-15
IL266519A (en) 2019-07-31
AU2024200737A1 (en) 2024-02-22
JP2019535822A (ja) 2019-12-12
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
MX364040B (es) 2019-04-11
PH12019501047A1 (en) 2019-12-11
ZA201903012B (en) 2020-09-30
RU2019116422A (ru) 2020-12-11
US20250325530A1 (en) 2025-10-23
JP2022173344A (ja) 2022-11-18
CA3043300A1 (en) 2018-05-17
CN110248646A (zh) 2019-09-17
US20230181550A1 (en) 2023-06-15
ECSP19031851A (es) 2019-06-30
MA45754A1 (fr) 2019-12-31
US20190262325A1 (en) 2019-08-29
PE20191149A1 (es) 2019-09-02
JOP20190102A1 (ar) 2019-05-06
RU2019116422A3 (enExample) 2021-04-09
CN115969802A (zh) 2023-04-18
WO2018088886A1 (es) 2018-05-17
CO2019004799A2 (es) 2019-07-31
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
MX2016014775A (es) 2018-05-10

Similar Documents

Publication Publication Date Title
US20250325530A1 (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
AU2015262214B2 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria
Ji et al. Daphnetin ameliorates experimental colitis by modulating microbiota composition and Treg/Th17 balance
Hu et al. Sodium tanshinone IIA sulfonate ameliorates ischemia-induced myocardial inflammation and lipid accumulation in Beagle dogs through NLRP3 inflammasome
Pavlová et al. The role of visfatin (PBEF/Nampt) in pregnancy complications
JP2018532779A (ja) 糖尿病及び腸疾患の治療又は予防における使用のためのフィーカリバクテリウムプラウスニッツィ及びデスルホビブリオピゲル
JP2022095884A (ja) 単離ミトコンドリアを含む関節リウマチの予防または治療のための医薬組成物
Alexandre et al. Lactose malabsorption and colonic fermentations alter host metabolism in rats
Joo et al. Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice
de Alencar et al. Low Irisin Levels in Patients with Type 2 Diabetes Mellitus without Current Treatment: A Systematic Review
KR20150050406A (ko) 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
Dai et al. Toll‐Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression
CN109550051B (zh) 组蛋白去甲基化酶kdm6a抑制剂在制备肥胖症治疗药物的用途
Sanhueza‐Olivares et al. Vascular remodelling in a mouse model of heart failure with preserved ejection fraction
Teixeira et al. Oral treatment with Hev b 13 ameliorates experimental colitis in mice
JP2020510001A (ja) 非アルコール性脂肪性肝疾患と非アルコール性脂肪性肝炎の予防および／または処置に使用するための化合物
JP6288757B2 (ja) 運動機能性向上剤
US20200360331A1 (en) COMPOSITIONS COMPRISING 15-HEPE AND/OR 15-HETrE AND METHODS OF TREATING OR PREVENTING CARDIOMETABOLIC DISEASE, METABOLIC SYNDROME, AND/OR RELATED DISEASES
RU2807743C1 (ru) Применение 5-пентадецилрезорцинола для повышения доли Akkermansia muciniphila в микробиоме человека
CN110870877A (zh) 戈氏副拟杆菌用于制备治疗慢性肾脏疾病的医药组合物的用途
Grond et al. Effects of the anti-inflammatory drug budesonide on the gut microbiota and cytokine production of 13-lined ground squirrels during prehibernation fattening
Askar et al. A Histological Study of The Protective Role of Intermittent Fasting and Probiotics on Indomethacin Induced Colitis in Adult Male Albino Rats.
CN103211804A (zh) 醋酸盐在制备改善糖尿病药物中的应用
Akhilesh Study of Clinical Profile and Significance of Serum Lipids in Psoriasis
ROSSI DAVID A. DORWARD| CHRISTOPHER D. LUCAS I KEITH C. ALLEN I ADRIANO G. ROSSI

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EXCALIBUR PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): CELL THERAPY AND TECHNOLOGY S.A. DE C.V.

FGA Letters patent sealed or granted (standard patent)